The Sabnis laboratory is investigating selective vulnerabilities in the way cancer cells choose to build, fold, and destroy their constituent proteins. We use patient-derived cell line and xenograft models to test the hypothesis that pediatric sarcomas - a deadly group of connective tissue cancers affecting children and young adults - are "primed" for drugs that disable protein homeostasis pathways.